 | • レポートコード：MRC2203A766 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の炭疽病治療市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、炭疽菌種類別（皮膚炭疽菌、吸入炭疽菌、胃腸炭疽菌、注射炭疽菌）分析、薬剤分類別（抗生物質、免疫グロブリン、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の炭疽病治療市場規模：炭疽菌種類別（皮膚炭疽菌、吸入炭疽菌、胃腸炭疽菌、注射炭疽菌） ・世界の炭疽病治療市場規模：薬剤分類別（抗生物質、免疫グロブリン、その他） ・世界の炭疽病治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Altimune Inc.、Elusys Therapeutics, Inc.、Emergent BioSolutions, Inc.、...） ・市場機会・将来の傾向 |
The anthrax treatment market will show rapid growth due to the increase in research funding and the development of novel therapies for the treatment of anthrax. The increasing public-private partnerships in order to facilitate the novel developments for the innovative and effective treatment of anthrax are also some of the factors expected to boost the growth of the anthrax treatment market.
There has been an increase in the development of novel therapies for anthrax due to the rising threat of exposure to Bacillus anthracis among civilian populations and military forces. Although clinical trials have been conducted to examine the safety and pharmacodynamics in humans, the efficacy studies are still inadequate. There are also novel antimicrobial strategies that are in the development to replace the antibiotics against anthrax bacilli.
The growing threat of exposure among the civilian population and military forces has thus led to the development of new therapies for anthrax treatment, which will make a positive impact on the growth of the global anthrax treatment market.
Key Market Trends
Cutaneous Anthrax Segment is Expected to Dominate the Anthrax Type Segment During the Forecast Period
By anthrax type, the market is segmented into cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax and injection anthrax. It has been found that in most of the reported cases, the cutaneous anthrax is found to be the most common anthrax, that is accounting for more than 80 per cent of the cases. As per the European Centre for Disease Prevention and Control, nine cases of cutaneous anthrax were reported from Hungary in 2014. Moreover, the transmission from the gastrointestinal route has also seen rising with increasing consumption of raw uncooked meat. Thus all these factors are expected to drive the overall market.
North America is Anticipated to Dominate the Anthrax Treatment Market
North America has dominated the global market owing to high government funding, supportive strategies, and the presence of key players in this region. There are also factors such as initiatives by organizations like the CDC supporting the development of novel therapies for the treatment of anthrax drives market growth in the Americas.
Europe is also expected to dominate the anthrax treatment market due to the high prevalence of anthrax in the region. Asia Pacific is also an another leading region in terms of market growth as anthrax is one of the common endemics in China, and in recent years, several anthrax outbreaks have been reported in China.
Competitive Landscape
There has been a presence of a considerable number of companies developing vaccines and therapeutics. There has been a presence of several companies that is quite intense. Factors such as the increase in the development of new therapies and an increase in research funding will provide considerable growth opportunities to anthrax treatment manufactures.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Research Funding
4.2.2 Development of Novel Therapies for Treatment of Anthrax
4.3 Market Restraints
4.3.1 High Cost Associated with Diagnostic Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Anthrax Type
5.1.1 Cutaneous Anthrax
5.1.2 Inhalation Anthrax
5.1.3 Gastrointestinal Anthrax
5.1.4 Injection Anthrax
5.2 By Drug Class
5.2.1 Antibiotics
5.2.2 Immunoglobulins
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Altimune Inc.
6.1.2 Elusys Therapeutics, Inc.
6.1.3 Emergent BioSolutions, Inc.
6.1.4 Porton Biopharma
6.1.5 Pfizer Inc.
6.1.6 Bayer AG
6.1.7 GlaxoSmithKline plc
6.1.8 Teva Pharmaceuticals
6.1.9 Eli Lilly and Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS